CHMP Recommends EU Approval For Eisai's Leqembi To Treat Early Alzheimer's Disease In Apolipoprotein E Ε4 Non-Carriers And Heterozygotes; Leqembi, A Monoclonal Antibody, Shown To Slow Cognitive Decline
CHMP Recommends EU Approval For Eisai's Leqembi To Treat Early Alzheimer's Disease In Apolipoprotein E Ε4 Non-Carriers And Heterozygotes; Leqembi, A Monoclonal Antibody, Shown To Slow Cognitive Decline
歐洲藥品評價委員會建議批准Eisai的Leqembi用於治療載脂蛋白E ε4非攜帶者和雜合子的早期阿爾茨海默病；Leqembi，一種單克隆抗體，已顯示能減緩認知能力下降
CHMP Recommends EU Approval For Eisai's Leqembi To Treat Early Alzheimer's Disease In Apolipoprotein E Ε4 Non-Carriers And Heterozygotes; Leqembi, A Monoclonal Antibody, Shown To Slow Cognitive Decline
歐洲藥品評價委員會建議批准Eisai的Leqembi用於治療載脂蛋白E ε4非攜帶者和雜合子的早期阿爾茨海默病；Leqembi，一種單克隆抗體，已顯示能減緩認知能力下降
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間